Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Parexel Chairman Josef von Rickenbach on Shifting CRO Models In Asia For Efficient Drug Development: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Roughly two-thirds of contract research organization Parexel's $1.1 billion 2010 revenue base was outside of the U.S., including about 12 percent in the Asia/Pacific region, and Chairman and CEO Josef von Rickenbach expects its share of APAC business to increase. In Tokyo for a day-long Parexel seminar to draw new clients in Japan, von Rickenbach and VP-Asia/Pacific Albert Liou spoke with PharmAsia News' Tokyo bureau about the company's shifting client base in Asia and the evolving partnership model in the CRO market in part one of this interview..

You may also be interested in...



Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development

The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.

Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development

The new openness provides opportunities for drug makers because it is no longer necessary to delegate all work to a Japanese partner, but the message is slow getting out.

Japan's Improved Clinical Trial Requirements Bring Positive Impact To China, Korea Development

TOKYO - Japan's drug regulator Pharmaceuticals and Medical Devices Agency has opened its doors in the last three years to preapproval discussions with drug companies. While the move has helped somewhat to ease the agency's drug approval lag, it can also pay benefits to companies applying for approvals in neighboring Asian countries

Related Content

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel